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ABSTRACT 
Since the introduction of Anti-Retroviral Therapy (ART) worldwide, Human Immunodeficiency 
Virus (HIV)-related morbidity and mortality has reportedly improved for many People Living 
With HIV/AIDS (PLWHA).  The treatment of HIV/AIDS (Acquired Immune Deficiency 
Syndrome) consists of taking a combination of three or more antiretroviral drugs (ARVs) known 
as Highly Active ART (HAART).     Chronic administration of HAART can lead to various 
adverse events that include mitochondrial toxicity which not only impacts adherence to therapy, 
but also patient safety.   Mitochondrial toxicity has been most commonly associated with 
stavudine (d4T). Mitochondrial toxicity may manifest as peripheral neuropathy, lactic 
acidosis/hyperlactatemia and lipoatrophy.   
 
The South African ART guidelines launched in 2004 uses d4T as part of the first line HAART 
regimen in the management of HIV/AIDS [National Department of Health (NDoH), 2004].   
This is a retrospective study of 803 enrolled HAART-naïve adult patients initiated on a d4T-
containing regimen between January 2006 and June 2009. The aim of the research was to 
quantitatively assess for the prevalence of mitochondrial toxicity as a result of d4T use in their 
individual regimens.   
 
A total of 120 (14.9%) of the study population (803) experienced peripheral neuropathy, with the 
majority reporting peripheral neuropathy within 6 months (median 5.9 months) after d4T 
initiation.  Twelve patients on concurrent anti-TB drug treatment complained of increased 
severity of peripheral neuropathy with d4T use. The blood lactate level of 70 patients were 
reviewed, 18 (8.7%) of the study population had lactate levels > 2.2mmol/l. Fourteen patients 
(1.7%) of the study population experienced lipoatrophy.  The mean duration before developing 
hyperlactatemia was 21.8 months (SD± 7.6) and 24.5 months (SD± 7.3) for lipoatrophy.   
 
An awareness of the early detection of symptoms associated with mitochondrial toxicity is useful 
to enable optimal clinical outcomes, and support adherence and compliance to therapy. In-service 
training of clinicians in pharmacovigilance protocols may also be improved.   
Since 2010, Tenofovir has been added to the first line regimen, and although d4t is no longer the 
first line ARV of choice, a large number of patients are still being maintained on a d4t-containing 
regimen. Finally, this research may be used in assessing the risk profile for patients being 
initiated on NRTI based regimens.  
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Chapter 1 
Mitochondrial Toxicities in HIV/AIDS Patients 
 
HIV remains the leading cause of mortality in Sub-Saharan Africa. Until recently, Antiretroviral 
Therapy (ART) for the treatment of HIV/AIDS was largely inaccessible because of the high cost, 
inadequate infrastructure, and concerns about suboptimal adherence (Desclaux et al., 2003; 
Laurent et al., 2005).  
  
UNAIDS (2010) estimates that there were 33.3 million (31.4 million–35.3 million) people living 
with HIV at the end of 2009 compared with 26.2 million (24.6 million– 27.8 million) in 1999- a 
27% increase. With an estimated 5.6 million (5.4 million–5.8 million) people living with HIV in 
2009, South Africa’s epidemic remains the largest in the world [World Health Organisation 
(WHO), United Nations Children’s Fund (UNICEF) & Joint United Nations Programme on HIV 
and AIDS (UNAIDS), 2010]. It is one of the few countries in the world where child and maternal 
mortality has risen since the 1990s (Every Death Counts Writing Group, 2008). HIV/AIDS is the 
largest cause of maternal mortality in South Africa and also accounts for 35% of deaths in 
children younger than five years (WHO, UNICEF & UNAIDS, 2010). AIDS-related deaths 
decreased by 18% in Southern Africa- an estimated 610 000 (530 000–700 000) people died 
from AIDS-related illnesses in Southern Africa in 2009, compared with 740 000 (670 000–
820 000) five years earlier. This is due to the significant scale up of ART over the past few years 
(UNAIDS, 2010). 
 
In 2009 alone, 1.2 million people received HIV antiretroviral therapy for the first time - an 
increase in the number of people receiving treatment of 30% in a single year. Overall, the 
number of people receiving therapy has grown 13-fold, more than five million people in low- and 
middle-income countries, since 2004. Expanding access to treatment has contributed to a 19% 
decline in deaths among people living with HIV between 2004 and 2009 (UNAIDS, 2010). 
 
Treatment with a combination of two NRTIs and Non-Nucleoside Reverse Transcriptase 
Inhibitor (NNRTI) or a Protease Inhibitor (PI) constitutes the HAART regime which is presently 
being adopted as the gold standard in the clinical management of HIV infections
 
[WHO/UNAIDS/IAS (International AIDS Society), 2000].  The National ART programme in 
South Africa, based on the HAART regime as suggested by WHO/UNAIDS/IAS, was launched 
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in April 2004
 
(NDoH, 2004). 
 
However, whilst drugs clearly provide many proven and potential benefits, any drug or medicine 
that is capable of producing a therapeutic or pharmacological effect can also produce unwanted 
adverse effects, either in isolation or in combination with other drugs or factors
 
(Teck and 
Donald, 2002).  A ‘safe’ drug is not risk-free, but “has reasonable risk given the magnitude of the 
benefit expected and the alternatives available” (FDA, 1999).   
 
Due to the great morbidity associated with HIV-1, the degree of toxicity considered reasonable 
for HAART is higher than that for other drugs (Carr, 2002).  The WHO defines an Adverse Drug 
Reaction (ADR) as “a response to a drug that is noxious and unintended and occurs at doses 
normally used in man for prophylaxis, diagnosis or therapy of disease or for modification of 
physiological function” (WHO, 1972). 
 
ART toxicity is an increasingly important issue in the management of HIV-infected patients.  
The principal toxicities of the licensed ARV drugs (Table 1) include mitochondrial toxicity, 
hypersensitivity, and lipodystrophy.  Mitochondrial toxicity includes peripheral neuropathy, 
lipoatrophy and lactic acidosis. 
 
 
Table 1: Antiretroviral agents approved by the FDA and Medicines Control Council (MCC) for 
treatment of HIV infection 
Drug Class Generic Name FDA Approval 
date 
MCC Registration 
date 
NRTIs Abacavir (ABC) February 1999 June 2001 
Abacavir/zidovudine/lamivudine November 2000 October 2003 
Didanosine (ddI) October 1991 July 1992 
Emtricitabine (FTC) July 2003  
Emtricitrabine/Tenofovir August 2004 May 2007 
Lamivudine (3TC) November 1995 June 1996 
Lamivudine/zidovudine November 2000 November 2000  
Stavudine (d4T) June 1994 November 1998 
Zalcitabine (ddC) June 1992 Not registered 
Zidovudine (AZT, ZDV) March 198 May 1989 
NtRTIs Tenofovir (TDF) October 2001 May 2007 
NNRTIs Delavirdine (DLV) April 1997 Not registered 
Efavirenz (EFV) September 1998 September 1999 
Nevirapine (NVP) June 1996 February 1998 
Fusion Inhibitors Enfuvirtide (ENF) March 2003 Not registered 
Maraviroc August 2007 Not registered 
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PIs Amprenavir (APV) April 1999 September 2001 
Atazanavir (ATV) June 2003  
Foramprenavir (FPV) November 2003 Not registered 
Indinavir (IDV) March 1996 October 1996 
Lopinavir/ritonavir (Lop/r) September 2000 August 2002 
Nelfinavir (NFV) March 1997 October 1999 
Ritonavir (RTV) March 1996 July 1997 
Saquinavir (SQV) hard gel 
capsules 
December 1995 January 1997 
Tripanavir (TPV) June 2005 Not registered 
Darunavir (DRV) June 2006 Not registered 
Source: Adapted from Bartlett et al., 2008 
 
Two ART regimens are recommended for use in the South African public sector
 
(NDoH, 2004). 
The first-line regimen is a d4T-containing regimen.  Factors in considering d4T for first-line 
therapy include lower cost; availability in dual and triple ARV combinations; has high initial 
adherence rates due to good gastrointestinal tolerance; does not require administration with food 
or large amounts of fluid (WHO: 2009).    
 
The recommended ART regimens are: 
 
Table 2: The South African National Department of Health 2004 recommended ART regimens 
Regimen ART Regimen 
1a Stavudine (d4T) 40mg (or 30mg if < 60kg)  12 hourly 
Lamivudine (3TC) 150mg 12 hourly 
Efavirenz (EFV) 600mg nocte 
1b Stavudine (d4T) 40mg (or 30mg if < 60kg) 12 hourly 
Lamivudine (3TC) 150mg 12 hourly  
Nevirapine (NVP) 200mg 12 hourly 
2 Zidovudine (AZT) 300mg 12 hourly 
Didanosine (ddI) 400mg daily (250mg daily if <60kg) 
Lopinavir/ritonavir (LPV/r) 400/100mg 12 hourly 
D4T is used as the first-line therapy in the HAART-naïve adult patient 
 
 
Mount Ayliff Anti-Retroviral Clinic, located in Mount Ayliff town, Eastern Cape Province, 
started in January 2006. It receives patients from surrounding public health facilities and a 
hospital viz, Tabankulu Health Centre, Mhlotsheni Clinic, Dundee Clinic, Lubaleko Clinic, 
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Mount Ayliff Gateway clinic, Ntsizwa clinic, Tela clinic and Sipetu Hospital. 
 
A descriptive study assessing the prevalence of peripheral neuropathy, lipoatrophy and 
hyperlactatemia/lactic acidosis in adult HIV/AIDS patients initiated on a d4T-containing regimen 
was conducted for all patients enrolled in the HIV/AIDS Comprehensive Care, Management and 
Treatment (CCMT) Programme.  
 
1.1 Aim and Objectives 
The aim of this study was to determine the prevalence of mitochondrial toxicity in adult 
HIV/AIDS patients initiated on a d4T-containing regimens. 
 
Due to the limited research available on the rural population of South Africa who access the 
public healthcare system, the impact of such toxicity on the success of the ART programme and 
quality of life of patients needs to be evaluated.   
 
The objectives in this study were as follows: 
1. To determine the prevalence of side-effects in patients initiated on a d4T-containing 
regimen and the effect of concurrent anti-TB drug use with d4T 
2. To determine the severity of side-effects in patients initiated on a d4T-containing 
regimen 
3. To determine the prevalence of the increase in severity of peripheral neuropathy 
with use of d4T 
4. To determine the prevalence for hyperlactatemia/lactic acidosis in pregnant patients  
and patients who weigh > 70kg on a d4T-containing regimen 
5. To determine the timeline between the initiation of d4T and the onset of clinical 
signs and symptoms of mitochondrial toxicity 
 
A patient risk profile will be compiled from the data above and used to decide on what the future 
initiation of HAART-naïve patients should be. 
 
1.2 Research Outcomes 
This study hoped to create an awareness of the early detection of clinical signs and symptoms 
associated with mitochondrial toxicity.  Early recognition and management will optimize the 
clinical outcomes of these patients whilst maintaining adherence and compliance to therapy and 
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reducing the significance of cosmetic changes if any.  In-service training of clinicians in routine 
monitoring of patients on ART will promote safety awareness and adverse drug reporting as well 
as identify preventable risk factors associated with mitochondrial toxicity (Pharmacovigilance). 
 
Conclusion 
The high HIV-associated morbidity and mortality reported in Sub-Saharan Africa affects 
therapeutic and clinical outcomes.  South Africa is reported to have the largest number of HIV 
infections worldwide and the SA government has made a concerted effort since 2004 to increase 
access and availability to treatment.  Global access to treatment has contributed to a 19% decline 
in deaths among people living with HIV between 2004 and 2009. ART toxicity is an increasingly 
important issue in the management of HIV-infected patients and includes mitochondrial toxicity, 
hypersensitivity, and lipodystrophy.  Research indicates that the prevalence of mitochondrial 
toxicity manifests as peripheral neuropathy, lipoatrophy and lactic acidosis. The prevalence of 
mitochondrial toxicity in the rural population at Mount Ayliff Hospital has not been investigated 
since the inception of the programme and the rollout of ART.  The impact of such toxicity on the 
success of the ART programme and quality of life of these patients would assist all health 
professionals in supporting and managing the clinical outcomes of the programme. 
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Chapter 2 
Literature Review 
Toxicities related to ART make long-term adherence to therapy difficult for patients and present 
challenges to providers, especially those in the resource-poor setting who work with a limited 
formulary.  Anti-Retroviral agents commonly used in resource-poor settings, such as d4T and 
ddI, have been associated with adverse events that are likely related to mitochondrial toxicity, 
whereas newer medications with fewer metabolic effects, like Tenofovir (TDF) and Abacavir 
(ABC), often are not available (Richard et al., 2007).  Although the prevalence and severity of 
treatment-associated toxicities have decreased in the developed world, the incidence remains 
relatively high in the developing world, primarily because of the use of older antiretroviral agents 
(Subbaraman et al., 2007). 
 
2.1 NRTI Pharmacology 
After Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are tri-phosphorylated intracellularly 
to nucleotides, they are incorporated in the growing Deoxyribonucleic Acid (DNA) chain by the 
viral enzyme reverse transcriptase, which prohibits further DNA elongation (NRTIs lack the 
critical hydroxyl group at the 3’-position of the sugar residue of the nucleotide). Other enzymes 
also capable of DNA formation (DNA-polymerases) can theoretically use these nucleotides as 
substrate and indeed, of the five known human DNA polymerases, both DNA polymerase β and 
γ have a high affinity for these compounds (Brinkman et al., 1998). The only exception for the 
inhibition of DNA polymerase γ is possibly Lamivudine (3TC), which at this moment is the only 
NRTI that acts as an inhibitor of the polymerase activity and concomitantly as a substrate of the 
integral 3`-5` exonuclease activity of this enzyme: incorporation is immediately followed by 
excision, enabling continuation of the DNA chain elongation (Gray et al., 1995).    
 
The cellular activation of NRTIs produces at least two distinct sets of pharmacokinetic 
dispositions, one for the biologically inactive drug in plasma and the other for the active NRTI 
phosphate in cells (Stretcher et al., 1994). Although underlying relationships probably exist 
between plasma NRTI concentrations and intracellular NRTI phosphate concentrations, these 
relationships are currently unpredictable in patients (Hoggard et al., 2002; Anderson et al., 2003).  
This is likely the result of rate-limiting or saturated-phosphorylation steps and the overall 
biological complexity of the system. A simplified diagram of the intracellular activation of the 
currently available NRTIs is shown in Table 3 (Kakuda, 2000; Van Rompay et al., 2000; Stein et 
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al., 2001). Most of the clinical manifestations of NRTI toxicities resemble mitochondrial 
diseases, and histologic evidence demonstrates abnormal mitochondria and/or mitochondrial 
DNA (mtDNA) depletion in affected tissues (Kakuda, 2000; Dalakas et al., 2001; Shikuma et al., 
2001; Bonnet et al., 2003). Studies show that NRTI triphosphates competitively inhibit mtDNA 
polymerase γ in vitro (Johnson et al., 2001). This, in turn, may decrease the number of 
mitochondrial respiratory chain proteins, inhibit aerobic respiration, induce oxidative stress, 
increase mutation in mtDNA, and result in mitochondrial and/or tissue failure (Lewis, 2001)  
 
Table 3: Cellular chemistry of NRTIs and NtRTIs 
Thymidine 
analogs 
ZDV                        ZDV MP → ZDV DP  
          Thymide kinase                 Thymidylate              5’NDPK 
                1 and 2                             kinase 
d4T                         d4T MP →  d4T DP  
 ZDV TP 
 
 
 d4T TP 
Cytidine 
analogs 
ddC                         ddC MP →        ddC DP            
FTC        dCK         FTC MP dCMPK  FTC DP 5’NDPK 
3TC                                    3TC MP → 3TC DP      
ddC TP 
FTC TP 
3TC TP 
 
 
Adenosine 
Analogs 
              5’NT                   AMPD 
ddI              ddl MP       ddA MP            ddA DP      
                                                        AMPK        
TDF           PMPA                                    PMPA MP           
         Cellular 
         Esterase 
 
 
ddA TP 
5’NDPK 
         PMPA DP 
 
Guanosine 
analogs 
ABV        ABV MP        CBV MP           CBV DP   
        APT                  AMPD                        gk                   5’NDPK 
        CBV TP 
Host-cell-mediated sequential enzymatic phosphorylation steps required for activating the 
nucleotide- and nucleoside-analogue reverse transcriptase inhibitors (NRTIs) to the triphosphate 
moiety. ABV, abacavir; AMPD, adenosine monophosphate deaminase; AMPK, adenosine 
monophosphate kinase (adenylate kinase); APT, adenosine phosphotransferase; CBV, carbovir; 
dCK, deoxycytidine kinase; dCMPK, deoxycytidinemonophosphate kinase; ddA, 2`,3`-
dideoxyadenosine; ddI, didanosine; DP, diphosphate; d4T, stavudine; FTC, emtricitabine; gK, 
guanylate kinase; MP, monophosphate; PMPA, tenofovir (PMPA DP is a triphosphate 
analogue); TDF, tenofovir disoproxil fumarate; TP, triphosphate; ZDV, zidovudine; 3TC, 
lamivudine; 5`NDPK, 5`nucleoside diphosphate kinase; 5`NT, 5`nucleotidase (Source: Anderson 
et al.  Clinical Infectious Disease.  2004; 38:743-53) 
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NRTIs are important drugs in the treatment of HIV infection. They disrupt the function of the 
viral reverse transcriptase enzyme, which results in the premature termination of viral DNA 
synthesis. NRTIs do not affect cellular DNA duplication because the enzymes implicated in this 
process have a proofreading mechanism. However, NRTIs can affect the mitochondrial genes 
(Lewis et al., 1994; Nusbaum et al., 1996). 
 
A pathway proposed to explain a link between the nucleoside analogues and toxicities such as 
lactic acidosis, peripheral neuropathy and lipoatrophy is mitochondrial toxicity (Cote et al., 
2002).  In vitro evidence suggests that d4T, ddI, and to a lesser extent AZT are inhibitors of 
mitochondrial DNA polymerase, whereas ABC and TDF are less potent inhibitors (Kakuda, 
2000; Reiss et al., 2004).  The use of d4T and ddI in combination appears to confer an especially 
high risk of complications (particularly peripheral neuropathy) and should be avoided (Robbins 
et al., 2003). 
 
Mitochondria replicate in cells independently of cell proliferation, according to the energy needs 
of the cell. The high sensitivity of mitochondrial DNA to NRTIs depends on a particular DNA 
polymerase (DNA polymerase γ), which directs DNA mitochondrial duplication. DNA 
polymerase γ has no proofreading function, so NRTIs can inhibit this enzyme in a manner similar 
to their effect on viral reverse transcriptase. When about 70% of mitochondrial DNA is damaged, 
cells begin to suffer from energy deficiencies and increase their anaerobic processes (glycolysis), 
with the production of lactic acid (Caffrey, 2000). Clinical expression of mitochondrial toxicity is 
determined by the organ system affected. For example, mitochondrial toxicity in the adipose 
tissue promotes lipoatrophy, whereas mitochondrial toxicity in liver promotes lactic acidosis 
(Kakuda, 1999). 
 
Mitochondrial toxicity may be covert or overt, which implies a threshold level of depletion for 
occurrence of clinical sequelae. The NRTI effect also may interact with other factors such as co-
morbid diseases. There also are genetic predispositions, as found in substudy of AIDS Clinical 
Trial Group (ACTG) 384, in which patients received the combinations of 3TC/AZT or d4T/ddl, 
each combined with Nelfinavir , Efavirenz, or both (Robbins et al., 2003). The result showed a 
highly significant over-representation of mitochondrial haplotype T in patients who developed 
peripheral neuropathy compared with control subjects (23% vs. 5%; P = 0.009; odds ratio: 5.4; 
95% confidence interval: 1.4-25.0), and the haplotype T was independently associated with the 
development of neuropathy, regardless of treatment received (Hulgan et al., 2005). 
9 
 
2.2 Peripheral Neuropathy 
Peripheral neuropathy, or distal sensory polyneuropathy (DSPN), is the most common 
neurological problem in HIV disease. DSPN also represents a complex symptom that occurs 
because of peripheral nerve damage related to advanced HIV disease and in association with the 
use of antiretroviral therapy-particularly in individuals treated with dideoxynucleosides (Nicholas 
et al., 2007). Distal painful sensorimotor polyneuropathy is clinically apparent in 10-30% of 
patients with AIDS. Subclinical forms occur in many more patients who are HIV positive 
(Morgello et al., 2004). DSPN is now commonly seen as a complication of ART, and it is 
particularly associated with the use of d4T or ddI (Cherry et al., 2006). 
 
 From 10% to 21% of persons exposed to d4T developed peripheral neuropathy in developed 
countries (Scarselle et al, 2002). Although symptoms usually resolve after prompt 
discontinuation of d4T therapy, persistent symptoms in a subset of patients may be problematic 
in developing countries, where many persons rely on physical labour for survival and usually do 
not have disability insurance. Cohort studies from Cameroon, India, and Thailand found 
peripheral neuropathy rates that were similar to, or, surprisingly, lower than those in developed 
countries (Kumarasamy et al, 2004; Laurent et al, 2004; Pujari et al, 2004). It is hard to establish 
whether these lower rates reflect under ascertainment biases (e.g. short follow-up periods and 
insensitive screening tools).  
 
In India, investigators reported that 13% of 183 patients receiving d4T, 3TC, and Nevirapine 
(NVP) who changed therapy, did so because of peripheral neuropathy, but the overall prevalence 
of DSPN was not reported (Kumarasamy et al., 2006).   
 
Of 264 patients in Malawi receiving d4T, 3TC, and NVP for at least 6 months, symptoms of 
numbness or pain in the lower extremities was reported in 56% (van Oosterhout et al., 2005).  
The authors noted that one-third of their patients had a body weight <60 kg, for which a 30mg 
dose of d4T is recommended; however, only the 40-mg dose was available in the fixed-dose 
combination (FDC) used in the study. This highlights the necessity of the availability of FDCs 
with varied doses to minimize toxicity, especially in malnourished patients. 
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In Uganda, Forna et al. (2007) reported that peripheral neuropathy was by far the most 
commonly reported toxicity among 1029 subjects receiving home-based ART in Tororo district, 
with 36% developing anti-retroviral toxic neuropathy, 9% severe. 
 
In South Africa, there are surprisingly few data.  One study reported that 6% of patients put onto 
a d4T-containing regimen switched due to peripheral neuropathy (Boulle et al., 2007). 
 
In a retrospective analysis of an observational cohort conducted between March 2003 and 
December 2010 in Cambodia, out of 2581 adult patients initiating a d4T-containing regimen, 
d4T was replaced in 276 (10.7%) patients for suspected d4T related neuropathy. The main early 
side effect was peripheral neuropathy (7.0% by 1 year), with a cumulative incidence of 16.6% 
and 19.0% by 3 and 6 years respectively (Phan et al., 2012).  From 2006 on, d4T was prescribed 
as 30mg bid (bis in die: twice daily), irrespective of body weight. Prior to that, dosing was done 
according to body weight with a higher dose (40 mg bid) for individuals with a body weight 
above 60 kg (WHO, 2006). 
 
HIV suppression was found to be similar in adult patients treated in South Africa with either the 
30mg or 40mg dose (Hoffmann et al., 2009); the incidence of peripheral neuropathy in adults 
treated in South Africa was significantly lower in the 30mg group than in the 40mg group, but 
the overall incidence was considered to be unacceptably high (Pahuja et al., 2010). 
 
In a longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV 
infected subjects, the proportion of patients diagnosed with peripheral neuropathy was 
significantly higher in the group receiving d4T-based therapy (17.1% vs. 11.2%; p <0.001) 
compared to those on non-d4T based therapy. Peripheral neuropathy was reported equally in both 
genders (approximately 17%), with no difference in time to development between the drug 
groups (Menezes et al., 2011). 
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2.3 Lactic Acidosis 
Lactic acidosis, a potentially fatal adverse effect of the nucleoside analogues, has emerged as an 
important toxicity, particularly in countries using d4T in the first-line therapy.  The growing 
evidence that d4T is closely linked with this toxicity is consistent with prior evidence from the 
developed world implicating this drug (Cornejo-Juarez et al., 2003; Geddes et al., 2006).   
 
Lactate is a normal metabolic end-product of glycolsis. It is formed when pyruvate reacts with 
reduced nicotinamide adenine dinucleotide (NADH) and is converted back to pyruvate by 
reactions with the oxidized counterpart of the dinucleotide (NAD
+
). Both reactions are catalyzed 
by the ubiquitous enzyme lactate dehydrogenase (LDH). Under normal aerobic conditions, 
pyruvate is further metabolized in the mitochondrion by oxidative phosphorylation to CO2, H2O, 
and ATP (Figure 1). During resting conditions, but especially during exercise, skeletal muscle is 
the most important producer of lactate, but in normal situations the liver (~50%) and, to a lesser 
extent, the renal cortex (~20%) guarantee an efficient clearance of this lactate from the 
circulation, which leads to a stable lactate concentration of ~1 mmol/L. Persistent 
hyperlactatemia (measured under resting conditions), therefore, only develops when this 
clearance mechanism is hampered (Madias, 1986). 
 
Increased lactate production can be induced either by anaerobic glycolysis or by a defect in the 
oxidative phosphorylation of peripheral tissue (e.g., muscle), but the finding of a persistently 
elevated lactate concentration in patients who are receiving NRTI therapy is more a reflection of 
an impaired hepatic lactate clearance than of an increased production. The sole pathway for 
lactate utilization is conversion back to pyruvate, which depends on efficient oxidative 
phosphorylation in the liver. An impaired lactate-clearance, therefore, can only be the result of a 
mitochondrial dysfunction in the hepatocytes (Fromenty et al., 1997). 
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Figure 1: Schematic representation of the cytosolic equilibrium between the conversion of 
pyruvate to lactate and the reconversion of lactate to pyruvate, mediated by the enzyme lactate 
dehydrogenase (LDH). (Source: Brinkman K. 2000. Clinical Infectious Diseases.  31:167-9) 
 
In South Africa, a report described the incidence of lactic acidosis in a cohort of 891 patients 
treated with d4T, 3TC, and EFV as being 19 cases/1000 person-years of treatment after an 
average of 7.5 months of receiving d4T.  All cases occurred in female patients (median body 
weight, 81kg), and the case mortality rate was 29% (Geddes et al., 2006). Pregnancy, renal and 
liver dysfunction may also place patients at elevated risk of lactic acidosis (Ivers et al., 2006). 
More recently, asymptomatic or mildly symptomatic hyperlactatemia without acidosis has been 
observed in 8–21% of persons receiving treatment with a NRTI and, less commonly, in HIV-
infected persons who have never received Combined ART (John et al., 2001). 
 
In another South African study, a significantly higher proportion of patients on stavudine-based 
therapy presented with symptomatic hyperlactatemia when compared to those on non-stavudine 
based therapy (5.75 vs. 2.2%, p < 0.0005), with females more frequently affected than males 
(7.1% vs. 2.5%; p <0.0001). Although the rate of development of lactic acidosis was the same for 
both drug groups, it was experienced more frequently in females than males (3.3% vs. 0.8%; p 
<0.0001), (Menezes et al., 2011). 
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In a cross-sectional analysis of 880 patients in a Swiss cohort, again, Stavudine treatment, 
especially in combination with Didanosine, was found to give an increased risk for elevated 
lactate compared with Zidovudine (Boubaker et al., 2001). However, when Stavudine was 
studied without Didanosine, the statistical significance of this finding got lost. In their cohort of 
2069 patients, Moyle et al., (2001) also found the highest prevalence of hyperlactatemia in 
Stavudine/Didanosine-treated patients (17.1%), but in their uni- and multivariate analysis, they 
conclude that especially current Didanosine use is the most significant risk factor, whereas no 
difference in risk factors was found for current Zidovudine or Stavudine use (Moyle et al., 2001). 
 
Phan et al., (2012), reported that in Cambodia, out of 2581 adult patients initiated on a d4T-
containing regimen, d4T was replaced in 14 (0.5%) patients due to symptomatic 
hyperlactatemia/lactic acidosis.  Symptomatic hyperlactatemia/lactic acidosis was mainly seen 
after the first six months but remained rare overall, with a cumulative incidence of 1% by 6 
years. 
 
2.4 Lipoatrophy 
Lipoatrophy is characterized by a loss of subcutaneous fat in the extremities, buttocks, and face 
and is closely associated with the use of nucleoside analogues that cause mitochondrial toxicity, 
such as d4T and ddI.  There is lower risk associated with AZT (Cornejo-Juarez et al., 2003).  
It occurs most often in patients treated with NRTIs with the greatest propensity to inhibit mDNA 
polymerase γ (Mallal et al., 2000). This study provided convincing substantiation of a 
quantitative link between mtDNA depletion and lipoatrophy and a further link to thymidine 
analogue therapy. Several clinical trials in antiretroviral-naive subjects have shown that treatment 
with thymidine analogue NRTIs leads to more lipoatrophy compared with treatment with other 
NRTIs (Gallant et al., 2004; Pozniak et al., 2006) as shown in Table 4. 
 
Table 4: GS 903 (Gilead 903 Study) and GS 934 (Gilead 934 Study):  
Differential effect of NRTIs on total limb fat 
            Mean Total Limb Fat, Kg (n) 
   Week 48   Week 96    Week 144 
Study 903 (Gallant, 2004)    
TDF + 3TC + EFV        -    7.9* (128)    8.6* (115) 
d4T + 3TC + EFV        -    5.0 (134)    4.5 (117) 
Study 934 (Pozniak, 2006)    
TDF + FTC + EFV     7.4† (51)    8.1*‡ (49)        - 
ZDV/3TC + EFV     6.0† (49)    5.5*§       - 
*P< .001, †P= .034, ‡P= .01, §P= .001 
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Studies of NRTIs involving enzyme assays and cell cultures have demonstrated that the 
hierarchy of mDNA polymerase γ inhibition is Zalcitabine ≥ Didanosine ≥ Stavudine > 
Lamivudine > Zidovudine > Abacavir (Kakuda. 2000). 
 
Consistent with this hierarchy, the NRTI, d4T has been shown clinically to place patients at a 
2.5-fold higher risk of developing lipoatrophy than does AZT (Mallal et al., 2000), and, that risk 
increases with duration of d4T treatment, concurrent elevation of serum lactate levels, and 
concurrent administration of Protease Inhibitors (PIs), (John, 2000). Stavudine is also believed to 
cause lipoatrophy by inducing adipocyte apoptosis (Caron et al., 2003). 
 
In the Mitochondrial Toxicity (MITOX) study, 111 patients receiving AZT or d4T- containing 
regimen were randomised to remain on the thymidine analogue or switch to ABC. A modest 
increase in the limb fat was observed in the ABC arm after 24 weeks. Limb fat continued to 
recover during extended follow-up, and 2 years after switching, approximately one third of limb 
fat loss had been recovered (Martin et al., 2004). In the Renal Atherososclerotic 
reVascularization Evaluation (RAVE study), 105 virologically suppressed patients receiving a 
d4T or AZT- containing regimen and who had clinical evidence of lipoatrophy were randomized 
to replace the thymidine analogue with either TDF or ABC. After 48 weeks of follow-up, limb 
fat measured by dual x-ray absorptiometry had increased significantly from baseline in both 
treatment arms and to a similar extent. Lipid changes were significantly more favorable in the 
TDF arm compared with the ABC arm (Moyle et al., 2006). 
 
Several clinical trials in antiretroviral-naive subjects have shown that treatment with thymidine 
analogue NRTIs leads to more lipoatrophy compared with treatment with other NRTIs (Gallant 
et al., 2004. 
 
In India, among 150 patients who initiated therapy with a regimen that included d4T and were 
followed for a mean of 19 months, investigators found lipoatrophy in 27%, compared with 10% 
of those initiating therapy with a regimen that included AZT (Joly et al., 2002). 
 
A retrospective analysis of an observational cohort in Cambodia, out of 2581 adult patients 
initiating a d4T-containing regimen, d4T was replaced in 957 (37.1%) for lipoatrophy. After the 
first year, lipoatrophy became the predominant side effect, with a cumulative incidence of 56.1% 
and 72.4% by 3 and 6 years respectively (Phan et al., 2012).  
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In Rwanda, among 141 patients’ (112 of whom were receiving d4T, 3TC, and NVP) body fat 
changes were found on physical examination in 24% (lipoatrophy 12%, mixed pattern 8%, 
lipohypertrophy 4%), (van Griensven et al., 2006). 
 
In a South African cohort of 8,497 initiated on a d4T-based therapy, 7.3% presented with 
lipoatrophy, compared to 4.6% (p < 0.05) patients on non-stavudine based therapy. The median 
time to development of lipoatrophy was similar across the two treatment groups. Lipoatrophy 
was more predominantly seen in female than male patients (10.0% vs. 1.6%; p < 0.0001) 
(Menezes et al., 2011). 
 
Conclusion 
Stavudine has been associated with adverse events of mitochondrial toxicity and evidence 
suggests that it acts as an inhibitor of mitochondrial DNA polymerase, thereby increasing the 
susceptibility to these adverse effects.  Peripheral neuropathy is reported to be the most common 
neurological problem in HIV disease, and is associated with d4T use.   Severity of neuropathy 
ranges across patients with some reporting resolution after discontinuation of d4T therapy.  
Lactic acidosis has been most often reported in female patients and is a potential fatal adverse 
effect.  Asymptomatic or mildly symptomatic hyperlactatemia without acidosis has been 
observed in patients receiving treatment with d4T. Another adverse effect with risks reported to 
increase with d4T use is lipoatrophy.  This has shown to be related to HIV infection and use of 
thymidine analogues.   
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Chapter 3 
Methodology 
Since the inception of the Mount Ayliff Hospital ARV Clinic in January 2006 until June 2009, 
there were 1300 patients initiated on ART with 822 adult patients on a d4T-containing regimen. 
The patient population was distributed as follows: 
 
Mount Ayliff Hospital ARV Clinic Population Distribution 
 
Figure 2: Pie chart of Mount Ayliff Hospital ARV Clinic Population Distribution 
 
From January 2006 d4T was used as the first line therapy in the HAART-naïve adult patient (d4T 
40mg or 30mg if < 60kg), (Table 1). During 2008, the use of a reduced dose of d4T (30mg), as 
recommended by WHO, was phased in for all patients on d4T 40mg.  Also in 2008, TDF was 
available strictly on a named patient basis for patients with a positive Hepatitis B surface antigen 
result.   
 
3.1 Study Population 
A retrospective study of all adult patients who were initiated from January 2006 to June 2009 on 
a d4T-containing regimen was done. Only patients who attended the Mount Ayliff Hospital ARV 
Clinic and who were treatment naïve to ART before initiation of triple ART (HAART) were 
reviewed.  
 
49 
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42 
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53 
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AZT-based regimen (2nd
line)
Age < 18 years
ARV-naive patients on
TDF
Loss to follow-up
Lost ARV folders
Adults on d4T-containing
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Patient screening included, patients on d4T, the concurrent administration of anti-TB drugs, 
pregnancy and weight >70kg. Lactic acid tests were performed for pregnant females, females 
with weight >70kg and patients presenting with signs and symptoms of hyperlactatemia/lactic 
acidosis.  Lactic acid tests were not routine.  In addition, the patients had to have had at least two 
follow-up visits after initiating HAART.  The patients’ history taken at each follow-up visit was 
assessed for the presence of: 
1. Peripheral neuropathy – The study investigated whether there was presence of 
symptoms before initiation of ART, presence with initiation of TB treatment, after 
initiation of ART, increased severity with concurrent use of ART and TB treatment. 
The diagnosis of peripheral neuropathy was made by a clinician who determined the 
characteristics of the pain (burning, tingling sensation) as experienced by the patients. 
As specified by the South African National Antiretroviral Treatment guidelines (2004), 
the severity of peripheral neuropathy is classified as follows: 
a). Mild - if the discomfort is mild and no treatment is required 
b). Moderate - if the discomfort is constant, but is relieved by narcotic analgesia 
c). Severe - if the discomfort is severe and is not relieved by narcotic analgesia 
2. Hyperlactatemia/Lactic acidosis – presence of symptoms (weakness, nausea, vomiting, 
abdominal pain etc). In asymptomatic patients, the lactic acid levels were recorded if  
pregnant and/or weight >70kg 
3. Lipoatrophy – presence of loss of subcutaneous fat in the face and extremities. This is 
diagnosed by symptom and signs of loss of subcutaneous fat e.g. prominent zygomatic 
arch on the face etc. 
 
Patients excluded from the study included patients on AZT and age < 18 years. Other risk 
factor for hyperlactatemia like- AZT, hepatitis C/ hepatitis B co-infection, liver disease, was 
not considered.  
 
3.2 Data Collection and Analysis 
Data analyzed was collected through the routine hospital monitoring system and the 
Pharmacovigilance form (Eastern Cape Regional Training Centre) (refer to Appendix C).   
The data was analyzed for variables using a checklist (refer to Appendix A).  This included age; 
sex; weight; concurrent use of TB treatment, pre- existing peripheral neuropathy, pregnancy and 
d4T-containing regimen. 
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Descriptive statistics was used to calculate the frequency, mean, median and standard deviation 
(SD) of the presence of peripheral neuropathy, lactic acidosis, lipoatrophy in patients on a d4T-
containing regimen including those who are pregnant and/or weight >70kg.   
 
The mean SD was used for variables that are normally distributed; and the median, 
interquartile range (IQR), and range, if required, was calculated for variables that were 
influenced by extreme values like death and hospitalization. 
 
The Adult Clinical Record and Pharmacy Order Form (refer to Appendix B) was used to monitor 
the patients’ progress, adherence and side-effect profiles after initiation of ART.    
 
3.3 Ethical Considerations 
To pursue this study, permission was sought from the management and quality assurance 
committee of the hospital through the medical manager after approval by the Departmental 
Research Committee and the University Ethics Committee (refer to Appendix F).   
Patient Informed Consent form and Consent for the Use of Pharmacy Folders for Perusal are 
attached in the Appendices D and E respectively as approved by the managing Responsible 
Pharmacist at Mount Ayliff Hospital ARV Clinic.  
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Chapter 4 
 Results 
This chapter describes how data has been analyzed and categorizes the prevalence of 
mitochondrial toxicity within the study population. It consists of 6 tables and figures with 
descriptions.  
 
4.1 Demographic and weight data of patients 
The folders of 822 patients on a d4T-containing regimen were screened for inclusion into the 
study, 803 folders were selected and reviewed. Nineteen did not return for follow- up and were 
excluded from the study.   
 
Two hundred and eighteen (27.1%) of the patients were males while 585 (72.9%) were females 
yielding a male-female ration of 1 to 2.7. 
 
The mean age of the patients in the sample was 38.4years, mode of 34.5years and a median age 
of 37.3years (interquartile range [IQR], 42.7- 57.1 years). Standard deviation (SD) ± 10years.  
 
The mean weight of the patients was 53.6kg± 11kg.   The modal weight was found to be 54.5kg 
and the median weight 52.8kg (IQR, 45.5- 59.3).  The majority of the patients (68.8%) were in 
the 40-59kg weight range. Table 5 demonstrates the distribution of weight in the study 
population at initiation.  
 
Table 5: Distribution of patients by weight  
Weight (kg) Number of patients Percentage 
30-39 57 7.1 
40-49 240 29.9 
50-59 312 38.9 
60-69 137 17.0 
70-79 34 4.2 
80-89 16 2.0 
90-99 7 0.9 
TOTAL 803 100 
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4.2 Lipoatrophy 
Lipoatrophy is the presence of loss of subcutaneous fat in the face and extremities. This is 
diagnosed by symptom and signs of loss of subcutaneous fat e.g. prominent zygomatic arch on 
the face etc. From the study population (803), the number of patients that complained of 
lipoatrophy and the diagnosis was made by a clinician after examination, was 14 (1.7%) with a 
95% confidence interval of 0.8 -2.6%. Six of these were males (42.9%), while 8 were female 
(57.1%). Table 6 and Figure 3 list the number of patients complaining of symptoms of 
lipoatrophy after 36 months on treatment.  
 
Table 6: Duration on d4T-containing regimen before complaining of Lipoatrophy 
Duration on treatment Number of patients Percentage 
1 – 6 months 0                   0 
7 – 12 months  1 0.1 
13 – 18 months 1 0.1 
19 – 24 months 6 0.8 
25 – 30 months 2 0.2 
31 – 36 months 4 0.5 
TOTAL 14 1.7 
 
The mean duration on treatment before diagnosis of lipoatrophy was 24.5 months 95% CI (19.3- 
28.9), median of 23.5 months, a mode of 21.5 months (IQR, 21- 43.25), SD± 7.3. 
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Figure 3: Graph of duration on d4T-containing regimen before developing lipoatrophy 
 
As can be seen in Table 6 and Figure 3, most patients tended to develop lipoatrophy from 19-24 
months. Lipoatrophy was found to be more prevalent in the female population, and to be more 
likely to manifest two years after being on a d4T-containing regimen.  
 
 
4.3 Lactic Acid/Hyperlactatemia 
Of the 803 patients on d4T-containing regimen, 70 were tested for hyperlactatemia/lactic 
acidosis; of which 8 (11.4%) was males and 62 (88.6%) was females. The normal range for 
venous blood lactate level is 0.5 – 2.2mmol/l. These 70 patients had symptoms of 
hyperlactatemia, pregnant, or weight > 70kg. 18 patients out of the 70 tested for 
hyperlactatemia/lactic acidosis had lactate level >2.2mmol/l.  This represents 2.2% [95% CI (1.2- 
3.2)] of the study population (803).  This is shown in Table 7.  
   
Table 7: Distribution of lactate levels within study population 
                Lactate level 
 <2.2mmol/l >2.2mmol/l 
Male 4 (5.7%) 4 (5.7%) 
Female 48 (68.6%) 14 (20.0%) 
Total 52 (74.3%) 18 (27.7%) 
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68.6% (48) of the women (n = 62), had lactic level <2.2mmol/l and 20% (14) had lactic level 
>2.2mmol/l. There were 16 pregnant women screened and all had lactic acid <2.2mmol/l. Fifty-
seven patients weighed >70kg which 81.4% of those tested for hyperlactatemia/lactic acidosis. 
 Forty four (77.2%) out of these 57 patients had lactic acid levels <2.2mmol/l while 13 (22.8%) 
had lactic acid level >2.2mmol/l. This showed that majority of patients who weighed more than > 
70kg had lactate levels within the normal range.  
 
The number of patients presenting with symptoms of nausea, vomiting, abdominal pain, etc was 
10 (7 females and 3 males), out of which 2 (20%) had lactic acid level <2.2mmol/l and 8 (80%) 
had lactic acid >2.2mmol/l.  
 
The mean duration of months before developing lactic acidosis/hyperlactatemia is 21.8 months 
95% CI (18- 25.6), a median of 21.5 months and a mode of 21.5 months (IQR, 16.25- 27.5), 
SD±7.6. None of the patients was diagnosed with lactic acidosis. 
 
Table 8 and Figure 4 list the number of patients who had elevated lactate level after 36 months 
on treatment. 
 
Table 8: The duration on d4T-containing regimen before developing Lactic Acidosis     
                /Hyperlactatemia (lactate level > 2.2mmol/l). 
Duration on Treatment Number of patients Percentage 
1 -6 months 0 0 
7 – 12 months 2 0.2 
13 – 18 months 4 0.5 
19 – 24 months 6 0.7 
25 – 30 months 3 0.4 
31 – 36 months 3 0.4 
Total 18 2.2 
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Figure 4: The duration on d4T-containing regimen before developing Lactic Acidosis 
                 /Hyperlactatemia (lactate level >2.2mmol/l 
 
The risk of increased lactic acid levels appeared to be more prevalent 18-24 months after being 
initiated on a d4T-containing regimen.   
 
4.4 Peripheral Neuropathy 
Out of the 803 patients initiated on a d4T-containing regimen, 303 (37.7%) complained of 
peripheral neuropathy before initiation of ARVs, 120 (14.9%) 95% CI (12.4- 17.4) complained 
of peripheral neuropathy after initiation of ARVs and 16 (2.0%) with no prior peripheral 
neuropathy, complained of peripheral neuropathy after initiation of TB treatment. Table 9 and 
Figure 5 show the prevalence of peripheral neuropathy.  
 
Table 9: Distribution of the presence of Peripheral Neuropathy 
Complaints Number of patients Percentage (%) 
No peripheral neuropathy reported 364 45.4 
Peripheral neuropathy before  initiating ARV 303 37.7 
Peripheral neuropathy after  initiating ARV 120 14.9 
Peripheral neuropathy after starting TB 
treatment 
16 2.0 
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Figure 5: Pie chart of patients presenting with Peripheral Neuropathy 
 
Of the 303 patients who complained for peripheral neuropathy before initiation of ARVs, 47 
(15.5%) of them complained of increase in severity in peripheral neuropathy with use of ARVs 
and 256 (84.5%) had no increase in severity with use of ARVs. The effect of concurrent use of 
anti- TB drugs on peripheral neuropathy was evaluated. The number of patients who were on 
ARVs and anti- TB drugs was one hundred and fifty-nine. Twelve (7.5%) had an increase in the 
severity of peripheral neuropathy while 147 (92.5%) had no increased effect.  
Table 10 shows the effects of ART on existing peripheral neuropathy prior to ART initiation. 
 
Table 10: Effects of d4T on existing Peripheral Neuropathy 
Severity of Peripheral neuropathy Number of patients 
Increase in severity 47 
No increase in severity 256 
TOTAL 303 
 
The presence of peripheral neuropathy after the initiation of ARVs was seen in 120 patients. The 
severity was classified into mild (if the discomfort is on/off and no treatment is required), 
moderate (if the discomfort is constant, but is relieved by narcotic analgesia), and severe (if the 
discomfort is severe and is not relieved by narcotic analgesia). This distribution is shown in 
Figure 6. The majority of these patients 73 (60.8%) complained of mild peripheral neuropathy, 
37 (30.8%) complained of moderate symptoms and 10 (8.4%) with severe peripheral neuropathy. 
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Figure 6: Pie chart showing the severity of Peripheral Neuropathy after starting d4T 
 
Of the 120 patients who presented with peripheral neuropathy after initiation of d4T, 67 
presented with peripheral neuropathy within the first six months on therapy while 25 presented 
with peripheral neuropathy within seven to twelve months on treatment. The mean of the 
duration on ARVs before the complaint of peripheral neuropathy is 9 months 95% CI (8.4- 10.4), 
the median of 5.9 months and mode of 3.5 months, (IQR, 3.2- 12), SD±8. 
 
The duration on a d4T-containing regimen before presenting with Peripheral Neuropathy is 
shown below in Figure 7. Peripheral Neuropathy presented within the first six months on 
treatment for patients initiated on a d4t-containing regimen, and diminished with time. 
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Figure 7: Duration on a d4T-containing regimen before presenting with Peripheral Neuropathy 
 
Figure 8 represents a combination of the signs and symptoms of mitochondrial toxicity as 
experienced by the patients. The trend for lactic acidosis /hyperlactatemia and lipoatrophy 
manifestations appeared to increase with time. 
 
 
 
 
Figure 8: Duration on d4T-containing regimen before presenting with Peripheral Neuropathy,  
                   Lipoatrophy and Lactic Acidosis/Hyperlactatemia 
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Conclusion 
The results of the 803 patients reviewed show the majority of the patients are female with a mean 
weight of 53.6kg.  This means that a majority of the patients would have being taking 30mg of 
d4T.  1.7% of these patients experienced lipoatrophy 19-24 months after starting a d4T-
containing regimen.  Hyperlactatemia was seen in 18 (2.2%) of the study population.  The 
pregnant female patients had a normal lactate level (0.5 – 2.2mmol/l) which differed from the 
literature which demonstrated pregnancy as a risk factor for hyperlactatemia.  This may be due to 
the ddI/d4T combination regimens used in pregnant patients as reported in the literature.  14.9% 
of the patients presented with peripheral neuropathy after d4T initiation, of which 8.4% was 
severe in nature.  Collectively the data showed that peripheral neuropathy occurred mostly in the 
first six months of treatment and the incidence declined as treatment progressed.  
Hyperlactatemia and lipoatrophy tend to occur after about 12 months after initiation as shown in 
Figure 8.    
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Chapter 5 
Discussion 
 
In this chapter, a summary of the study is provided. The patient profile and prevalence of 
mitochondrial toxicity in the study population is discussed and compared with the literature.   
 
5.1 Population Profile 
Mount Ayliff Antiretroviral clinic started initiating patients on ART in January 2006. In line with 
the WHO recommendations, the South African National Antiretroviral treatment guidelines, first 
edition 2004, indicated the use d4T 40mg every 12 hours (30mg every 12 hours if body 
weight<60 kg) in adults and adolescents. A total of 822 adult patients on a d4T-containing 
regimen, 803 were selected and reviewed for this study.  
 
The mean weight of this population was 53kg. 609 (75.8%) of the study population had weight 
between 30- 59 kg. These patients were started on a d4T dose of 30mg. A meta-analysis from 
randomised control trials and cohort studies showed that switching from higher to lower doses of 
d4T, or starting at lower doses, is associated with improvement in d4T toxicity without loss of 
efficacy (Hill et al., 2007). 
 
Clinical experience with d4T has been extensive. It has a favourable resistance profile, good 
short-term tolerability, does not require dietary restrictions and, due to its relatively low cost, is 
still widely used. However, d4T has been associated with a higher risk of mitochondrial DNA 
depletion and adipocyte metabolic dysfunction compared with other nucleoside with other 
NRTIs (Nolan et al., 2003) which may contribute to the pathogenesis of subcutaneous fat 
wasting, and the development of lipoatrophy and metabolic complication (Dube et al., 2005).  
 
The following two main approaches have been used to reduce the toxic effects of d4T: 
replacement of d4T by potentially less toxic agents, usually Tenofovir (Domingo et al., 2004; 
Moyle et al., 2006) or Abacavir (Carr et al., 2002; Martin et al., 2004); or more recently a d4T 
dose reduction (Martin et al., 2004; Moyle et al., 2006). Results obtained mainly from cohort 
studies, show that a d4T dose reduction strategy may lead to a modest reversal of side-effects 
(Sanchez-Conde et al., 2005). 
 
 
 
29 
 
Switching to lower doses of d4T was associated with decreased drug exposure, mitochondrial 
DNA repletion, partial reversal of lipoatrophy, improvement in lactate and lipids (Hill et al., 
2007; McComsey et al., 2008; Ait-Mohand et al., 2008). 
 
Out of 2190 adults (median follow-up: 1.5 years) in Rwanda, d4T was replaced in 175 patients 
(8.0%) for neuropathy, 69 (3.1%) for lactic acidosis and 157 (7.2%) for lipoatrophy, which was 
the most frequent toxicity by 3 years of antiretroviral treatment (ART). Use of d4T 40 mg was 
associated with increased risk of lipoatrophy and early (<6 months) neuropathy (van Griensven 
et al., 2009). 
 
It seems that d4T toxicity is cumulative, as it is shown to be dose related and is associated with 
prolonged duration on treatment (Hill et al., 2007). Following a meta-analysis showing lower 
doses were safer and as effective, WHO issued a statement that only low dose d4T (30 mg) 
should be used (Hill et al, 2007). In compliance with this finding, the Eastern Cape province 
recommended that all patients on d4T 40mg be changed to d4T 30mg and all new patients be 
initiated on d4T 30mg irrespective of weight in 2008. The 40mg d4T was gradually phased out.   
   
5.2 Lipoatrophy 
The result of this study showed that d4T- associated lipoatrophy was seen in 1.7% of patients. 
This was less than observed by Joly et al, 2002; Pujari et al, 2005. In a South African cohort of 
forty seven participants, 34% had lipoatrophy (Sinxadi et al., 2010). A meta-analysis from 
randomised control trials and cohort studies showed that switching from higher to lower doses of 
d4T, or starting at lower doses, is associated with improvement in d4T toxicity without loss of 
efficacy (Hill et al.,2007). Switching to lower doses of d4T was associated with decreased drug 
exposure, mitochondrial DNA repletion, partial reversal of lipoatrophy, improvement in lactate 
and lipids (Hill et al, 2007; McComsey et al, 2008; Ait-Mohand et al, 2008). 
 
The patients at Mount Ayliff Antiretroviral clinic were on 30mg d4T irrespective of the weight. 
This might explain the lower number of lipoatrophy that was reported in this study when 
compared to other studies. 
 
Benefits of a d4T dose reduction and /or switching to TDF were also observed by total body 
Dual- Energy X-Ray Absorptiometry (DEXA) scan, showing a median increase in peripheral and 
total fat compared with baseline values. Although the median increase was higher in the d4T 
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(30mg) arm compared with the TDF arm, only those changes in the TDF arm reached statistical 
significance when compared with the d4T (40mg) arm. Values in subcutaneous fat continued to 
decrease in the d4T (40mg) arm, compared with baseline, but did not reach statistical 
significance (Milinkovic et al., 2007). 
 
The effect of reduced d4T dosage on lipoatrophy and viral failure was evaluated in an 
observational cohort of 80 patients in Thailand (Hanvanich et al., 2003). Before reducing the 
dose of d4T all patients developed lipoatrophy. In patients weighing ≥ 60 kg the d4T dose was 
reduced to 30 mg 12 hourly and in patients weighing < 60 kg the d4T dose was reduced to 20 mg 
12 hourly. After 93 weeks, all patients maintained a plasma viral load of < 50 copies/mL. All 
patients had an improvement in lipoatrophy with the d4T dose reduction. The improvement was 
much faster for mild lipoatrophy cases than for moderate and severe lipoatrophy cases. 
 
The data observed at Mount Ayliff demonstrates that lipoatrophy did not often present in the first 
six months after d4T initiation.  The median duration of d4T exposure is 23.5 months. This is 
higher than reported by Sinxadi et al (2010) which reported a median of 14.5 months.   
According to Urbina et al. (2005), 71% of patients taking low dose d4T were free of 
lipodystrophy after 5 years on treatment. This showed that long term use of low dose d4T is well 
tolerated.  
 
In our study at Mount Ayliff Antiretroviral Clinic more women were diagnosed with lipoatrophy 
than men, further studies can be conducted to assess the trend of lipoatrophy amongst men and 
women.  The reason for variation in lipoatrophy rates found in this study compared to others 
could be due to varying diagnostic criteria.   
 
5.3 Lactic acid/Hyperlactatemia   
8.7% (70) of the study population met the criteria for lactate evaluation and were tested for 
hyperlactatemia/lactic acidosis. Eighteen of these patients had a lactic acid level > 2.2 mmol/l.  
This is less than reported by Bolhear et al, 2007.  The high incidence of lactate in their study may 
be due to the use 40mg d4T and the concomitant use of d4T and ddI. This possibility is 
supported by observations that patients on higher dose stavudine (40 mg twice daily) have a 
higher incidence of elevated lactate than those who receive lower doses (20 or 30 mg twice daily) 
(van Griensven et al., 2009). 
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In Botswana ARV related toxicities were assessed in 650 patients, who were required to be on 
ARVs for ≥ 2 years at the start of the study. There were 19 events in which patients had a serum 
lactate > 4.4 mmol/L, 15 of which were moderate or worse in severity. These episodes occurred 
in females who were on combined Antiretroviral Therapy for a mean of 10.2 months. Twelve of 
these 15 patients were on d4T. There were seven episodes of lactic acidosis. All seven patients 
were receiving d4T and/or ddI containing therapy (Wester et al. 2007). 
 
This was different from our clinic where all patients received 30mg d4T irrespective of the 
weight, and concomitant use of d4T and ddI were not used as part of the recommended treatment 
guidelines. This was consistent with findings of another study conducted in Spain which reported 
that d4T- low doses resulted in a significantly better outcome in terms of efficacy and toxicity 
profile than d4T-standard doses (Ribera et al., 2005).   
 
Gerard and colleagues described 14 cases of hyperlactatemia in a cohort of 871 patients; the 
incidence was 0.8% per year which rose to 1.2% per year if only patients on d4T-containing 
regimens were included (Gerard et al., 2000). 
 
None of the pregnant women (n=16) in our clinic study had elevated lactate levels. There was no 
confirmed case of lactic acidosis, most likely due to the absence of laboratory results for serum 
bicarbonate level and arterial pH. These two results are important to diagnose lactic acidosis. 8 
(1%) of the 70 patients had symptomatic hyperlactatemia.   
 
A Spanish study concluded that symptomatic hyperlactatemia was reported in 0.2 to 2.5% of 
infected adults and the syndrome of lactic acidosis /hepatic steatosis was rare (Falco et al 2002).  
Another study conducted in Botswana reported that approximately 1% of individuals starting 
antiretroviral therapy with a d4T-containing regimen developed lactic acidosis (Wester et al, 
2007). Carter (2007) commented that the incidence of lactic acidosis found in Botswana was 
significantly higher than that seen in industrialized countries. The findings in this study are 
contradictory with the following findings in studies conducted in Europe (Gerard, 2000; 
Vrouenraets, 2002; Falco, 2002).  
These complaints were more likely to be reported by females, and it appears that females are 
more likely to be pre-disposed to lactic acid level > 2.2 mmol/l than males.   
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5.4 Peripheral Neuropathy 
Peripheral neuropathy, or DSPN is the most common neurological problem in HIV disease 
(Nicholas et al., 2007) and is a well described side-effect of treatment with d4T (Browne et al., 
1993; Skowron et al., 1995) and other antiretroviral drugs (Carr et al., 2000).  
 
It is also the most frequent side-effect reported in our clinic. 14.9% of patients complained of 
peripheral neuropathy after initiation with d4T which is less than reported by Forna et al. (2007); 
Cherry et al. (2009); but in line with Kumarasamy et al. (2006); and Scarselle et al. (2002). 
According to Markison et al (2008) in resource limited settings, results shows that first line ARV 
containing d4T was used for clinically eligible patients.  13% of patients were diagnosed with 
peripheral neuropathy and 6% switched to AZT as it is used as a substitute for d4T. 
 
The lower prevalence of peripheral neuropathy in our patients compared to those reported by 
studies in Malawi and Uganda may be due to the use of lower dose d4T (30mg).
 
Peripheral 
neuropathy occurred after a median of 5.9 months, which is longer than previously described by 
Simpson and Tagliati (1995). 8.4% of the peripheral neuropathy were severe (if the discomfort is 
severe and is not relieved by narcotic analgesia) which is similar to that reported by Forna et al. 
(2007); van Griensven et al. (2009). 
 
 
In our cohort, HIV-associated peripheral neuropathy was reported by 37.7% (303) of patients. 
This was similar to that observed by Morgello et al. (2004).  Symptoms of peripheral neuropathy 
reported by patients, included numbness/tingling of extremities, varied levels of discomfort and 
some pain.  
 
 It is important to communicate to patients that they may also experience drug-induced peripheral 
neuropathy which may exacerbate the condition. In those patients with pre- existing peripheral 
neuropathy, 15.5% reported worsening of peripheral neuropathy with initiation of d4T.  The high 
number of patients who report peripheral neuropathy prior to ART initiation also infers that the 
prevalence of peripheral neuropathy in patients may be much higher and may have an impact on 
patient clinical outcomes and adherence to HAART.     
 
Concomitant administration of TB treatment and HAART is common in sub-Saharan Africa, 
especially at HAART initiation. Peripheral neuropathy is caused by both Isoniazid (Subbaraman 
et al., 2007) and d4T (Breen et al., 2000; Dean et al., 2002; Amoroso et al., 2007; Boulle et at., 
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2007; Hawkins et al., 2007), through different mechanisms; use of both drugs may lead to an 
additive or cumulative effect and increase the severity of symptoms. 
 
 7.5% (12) of patients on concomitant administration Isoniazid and d4T complained of increase 
in severity of peripheral neuropathy.  These results may understate the true impact of 
concomitant d4T and TB treatment because the great majority of patients with TB in South 
Africa are prescribed vitamin B6 (pyridoxine) at the time of initiation of TB treatment for the 
prevention of peripheral neuropathy, and in addition, Amitriptyline is frequently prescribed to 
manage incident peripheral neuropathy. It is possible that the effect of TB treatment on the risk 
of d4T substitution would be even higher in settings where these drugs were not routinely used; 
conversely, rates of peripheral neuropathy may be further reduced with additional micronutrient 
supplementation (Villamor et al., 2008). 
 
Close to 2% reported peripheral neuropathy after starting TB treatment; however the study did 
not ascertain in total how many patients were tested and treated for TB, but merely the number 
who reported. This might be explained by the fact that the National TB Programme was not 
integrated into the ART programme. Peripheral neuropathy has no permanent cure, and is 
symptomatically managed using pyridoxine, tri-cyclic antidepressants and Non-Steroidal Anti-
Inflammatory Drugs (NSAIDS).  Reporting of peripheral neuropathy is erratic and as patients 
adapt to it, it is not commonly reported. Co-infected HIV and TB patients must be routinely 
screened and managed for peripheral neuropathy. The subjective measurement of peripheral 
neuropathy severity is not reliable as tolerance and pain levels are different for any individual.  
The majority of patients reported no increase in severity of pre- existing peripheral neuropathy 
after initiation.  
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Chapter 6 
Conclusion and Recommendations 
The study has shown that mitochondrial toxicity is prevalent in adult HIV/AIDS patients initiated 
on a d4T-containing regimen at Mount Ayliff Antiretroviral Clinic.  A retrospective study 
conducted using 803 patients’ records were reviewed, of which 1.7% had lipoatrophy, 2.2% 
hyperlactatemia and 14.9% peripheral neuropathy.   
 
Peripheral neuropathy was the side-effect most prevalent amongst the study population across 
both genders. Hyperlactatemia, though not actively observed, must be screened for regularly 
especially in pregnancy and weight >70kg which are high risk factors for lactic acidosis.  
Lipoatrophy was found to be most likely prevalent amongst females initiated on d4T.   
 
The prevalence rates of mitochondrial toxicity appeared to be much lower than other studies, and 
this lower prevalence may be due to the use of d4T 30mg dose in all patients initiated on 
HAART and the non-concomitant use of d4T and ddI in therapy.  WHO recommended the use of 
lower dose d4T because of the evidence from several studies that showed that lower dose d4T 
had a better side-effect profile.   
 
The study showed that peripheral neuropathy had an early onset, within the first 6 months on 
therapy, which could be exacerbated by concurrent administration of anti-TB drugs.  
Hyperlactatemia and lipoatrophy manifested with long-term d4T use.   
 
The importance of screening for mitochondrial toxicity in patients on d4T-containing regimens, 
and the early detection of possible risk factors for mitochondrial toxicity as a routine clinical 
assessment, may work towards improving clinical outcomes, adherence to therapy and quality of 
life for patients on therapy.  
 
A patient risk profile compiled from ART preparation to initiation and continued throughout 
therapy would be useful in creating individual patient care plans and side-effect profiles and as 
tools for managed care, pharmacovigilance and in-service mentoring.    This would also be useful 
as an indicator in the HIV/AIDS CCMT programme outcomes for many patients initiated who 
transfer, default or are a loss to follow-up due to the debilitating effects of mitochondrial toxicity.    
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Newer drugs with safer side-effect profiles, like Tenofovir, means that the use of d4T will 
decrease, however stable patients on d4T will need to be monitored regularly. Since 2010, 
Tenofovir has been added to the first line regimen, and although d4t is no longer the first line 
ARV of choice, a large number of patients are still being maintained on it. Continuous follow- up 
of these patients is important for detection of symptoms and management of mitochondrial 
toxicity.  
 
 
Following this study, the proposed recommendations for best practice are: 
 
1. Individual side-effect profiles for all patients should be routinely updated and 
monitored for changes in severity of side-effects experienced, frequency and treatment 
management 
2. Establishment of a functional Pharmacovigilance committee within the ARV Clinic to 
promote safety awareness and side-effect and ADR reporting 
3. Implementation of screening protocols to assist health care workers in health promotion 
activities and patient education of HAART 
4. Implementation of revised standard treatment guidelines of newer drugs with safer side-
effect profiles 
5. On-going in-service education and clinical mentoring in HIV management 
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Appendix A.  Patient Checklist for inclusion into study 
 
MOUNT AYLIFF HOSPITAL 
Batho Pele /Abantu Kuqala/People First 
ISEBE LEZEMPILO DEPARTMENT OF HEALTH 
Ingxowa Eyodwa/Private Bag X 504, MOUNT AYLIFF 4735 
__________________________________________________________________________________ 
ARV CLINIC 
CHECKLIST FOR INCLUSION INTO STUDY  
 
ARV Clinic number:                                                                                    
Date of ART initiation: 
 
CD4 at treatment initiation:                           
Regimen:  
 
Age: 
Sex: 
Weight at initiation:                                       
BMI at initiation:                                                    
 
Pregnancy: 
Concurrent use of TB treatment: 
Pre-existing peripheral neuropathy or DSN: 
Lactate level >2mmol/l: 
Loss of subcutaneous fat: 
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Appendix B.  Adult Clinical Record 
 
 
 
MOUNT AYLIFF HOSPITAL ARV CLINIC 
ADULT CLINICAL RECORD 
 
HOSPITAL/CLINIC:  
PATIENT NO. :  
 
NAME  
DATE OF BIRTH  
ID NUMBER  
ADDRESS 
 
 
CONTACT NUMBER  
(INCLUDE SUPPORTER) 
 
 
GENDER          M                     F HEIGHT (in cm) 
ALLERGY (ies)  
DATE OF FIRST HIV TEST  
WHO stage (at enrolment)  
 
Past Medical and Drug History – concurrent illness and medications 
 
 
 
*REASON FOR CHANGING MEDICATION* 
1.  TOXICITY / SIDE-EFFECT     2.  TREATMENT FAILURE     3.  POOR 
ADHERENCE 
4.  DRUG INTERACTION            5.  PREGNANCY                     6.  PATIENT   
                                                                                                           PREFERENCE 
7.  DRUG O/S                                 8.  TRANSFER TO ANOTHER PROGRAM 
9.  IRIS                                            10.  OTHER (specify) 
** ARV REGIMEN START DATE STOP DATE REASON* 
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** ANTI-RETROVIRAL ABBREVIATIONS 
NRTI     d4T  = Stavudine   3TC = Lamivudine    AZT = Zidovudine   ddI = Didanosine 
NRTI     EFV = Efavirenz                                      NVP = Nevirapine 
PI           LPV/r = Lopinavir/ritonavir                    RTV = Ritonavir 
 
 
 
ARV REGIMEN 
Regimen 1a d4T / 3TC / EFV 
Regimen 1b d4T / 3TC / NVP 
Regimen 2 AZT / ddI / LPV/r 
 
ARV TREATMENT START DATE  
CD4 AT START OF TREATMENT  
VIRAL LOAD AT START OF TREATMENT  
WHO STAGE AT START OF TREAMENT  
 
Date of visit  
Month  / year on Rx  
Social Grant           Y/N  
Nutrition support    Y/N  
Pregnancy               Y/N  
LMP  
Weight   
VITAL SIGNS 
Temperature  
BP  
Pulse  
Respiration Rate  
ADHERENCE 
# of missed doses last week  
# of missed doses last month  
Rx interruption (unintentional) # of days  
LAB RESULTS 
CD4 Count / CD4 %  
Viral Load  
ALT  
AST  
Creatinine  
Haemoglobin  
AFB  
Cholesterol  
Blood Sugar  
RPR  
PRESENTING COMPLAINT 
None  
Recent weight loss  
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Fever  
Night sweats  
Headache   
Cough > 2 weeks  
 
Shortness of breath  
Nausea / vomiting  
Chronic diarrhoea  
Pain when swallowing  
Numbness / tingling  
New visual problems  
New swelling  
OPPORTUNISTIC INFECTIONS or AIDS DEFINING ILLNESS 
None  
Pulmonary TB  
Extrapulmonary TB  
PCP  
Pneumonia  
Oral candidiasis  
Oesophageal candidiasis  
Diarrhoea / wasting  
Herpes zoster  
Herpes Simplex  
Cryptococcal meningitis  
Encephalopathy / dementia  
Urethritis / cervicitis  
Genital ulcerative disease  
Steven-Johnsons Syndrome  
PID  
Cutaneous Karposi’s Sarcoma  
 
 
 
ARV SIDE-EFFECT yes/no 
None  
Headache  
Anaemia  
Severe nausea and vomiting  
Diarrhoea   
Hyperlipidaemia  
Hyperglycaemia  
Rash   
Steven- Johnsons Syndrome  
Hepatic toxicity  
Liver failure  
Peripheral neuropathy  
Lipoatrophy   
Pancreatitis   
Lactic acidosis  
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Insomnia  
Psychosis or hallucinations  
Suicide attempt  
Renal insufficiency  
Renal failure  
 
 
 
 
ASSESSMENT on day of visit 
Improving / stable  
Active OI  
Drug toxicity   
Non-adherence  
WHO stage  
WAB  
PLAN 
Continue current Rx  
Restart Rx  
Start new Rx ( naïve patient)  
Change regimen* (indicate code)  
Stop Rx* (indicate code)  
Regimen   
MEDICATIONS 
TB Medication  
Vitamins  
Inj contraceptives  
Insomnia  
Psychosis or hallucinations  
Condoms  
Other   
 
 
 
Appointment date  
Attending clinician / nurse  
Signature  
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Appendix C.  Adverse drug reaction and product quality problem report form: HIV/AIDS 
Treatment Programme                                       
 
 
ADVERSE DRUG REACTION AND PRODUCT 
QUALITY PROBLEM REPORT FORM 
HIV/AIDS Treatment Programme  
Eastern Cape Regional Training Centre (ECRTC) 
Main number Tel (047)                      Main fax # (047) 
In collaboration with the Provincial HIV/AIDS Programme and MCC 
(Please Place Original Form in the patient records and Send duplicate to the RTC)  
PATIENT DETAILS 
Name (or initials)……………………………………… Age……………………….
  
Weight (kg) …………………… 
 
Gender M/F
  
Allergy …………………………………
 Height (cm) …………………... 
ADVERSE DRUG REACTION/PRODUCT QUALITY PROBLEM 
Date of onset of reaction..…./…./……….  
 Time of onset of reaction ……..h……min 
 Adverse reaction and/or  
 Product quality problem  
Description of reaction or problem (circle all relevant reactions) – Attach additional information 
as required 
 Pain/tingling/numbness in    
extremities 
 Abdominal or back pain 
 Nausea/vomiting/diarrhoea 
 Persistent muscle pain 
 Anxiety/depression 
 Unusual fatigue 
 Chills/fever 
 Unusual bruising/bleeding 
 Rash 
 Dizziness 
 Insomnia 
 Head ache 
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 Other______________ 
 Other______________ 
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1.MEDICINES (CONCOMITANT MEDICINES INCLUDING HERBAL PRODUCTS IF KNOWN) 
Trade name and 
batch no. 
* Suspected drug 
 
Daily dosage 
 
Route 
 
Date Started 
 
Date Stopped 
 
Reasons 
of Use 
Prescriber 
Doctor, Nurse 
or Other 
1a,  1b,  2  NA, NP, AD PO   HIV Tx,  
       
       
Keys: 1a = d4T/3TC/EFZ, 1b = d4T/3TC/NVP, 2 = AZT/ddI/lop-Rit (Circle one of the ARV Tx regimen). NA = Normal adult 
dose, NP = Normal paediatric dose, AD = adjusted dose (please specify on the back page)  
ADVERSE REACTION OUTCOME (MAKE A MARK ON THE CHECK-BOX OF ALL THAT APPLY) 
Action Taken  Patient Outcome  Intervention Required  
 Discontinued Suspected drug 
 Decreased dose 
 Other drug used to treat ADR   
             (Name and dose) 
 Other (specify) ……………… 
…………………………………………….. 
 Symptoms--- Improved----resolved 
 Permanent significant disability 
 Congenital abnormality 
 Life threatening 
 Death 
 Other 
 Patient counselled 
 Referred to expert for input 
 Additional Clinic Visit 
 Additional labs requested 
 Hospitalisation 
 Other 
Important Laboratory Values: Circle abnormal one and write the values: BL=baseline Cur=current 
Hgb ALT: Neutro Cholesterol LACT: K+ Serum Cr. Other_____ Other_____ 
BL:        
Cur:        
Relevant clinical history (Attach additional information) 
 How long has patient been diagnosed of HIV: _______ years 
 How long has patient been on ARV treatment: ________ months 
 Other concomitant conditions (Circle one): HTN, Diabetes, KS, others ____________________ 
Additional Information_______________________________________________________________ 
2.PRODUCT QUALITY PROBLEM (PRODUCT AVAILABLE FOR EVALUATION Y/N) 
Trade name Batch no. Registration no. Dosage form 
and strength 
Expiry date Size/Type 
of container 
      
      
 
 
Reporting Doctor/Pharmacist/Nurse etc: 
Name    _________________________ Qualifications _____________________________ 
Facility   _______________________ 
Tel (____)_______________________  
Signature ______________________                                     Date _______________ 
This report does not constitute an admission that the medical personnel or product caused the event 
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Appendix D.  Patient Informed Consent Form 
 
 
MOUNT AYLIFF HOSPITAL 
Batho Pele /Abantu Kuqala/People First 
ISEBE LEZEMPILO DEPARTMENT OF HEALTH 
Ingxowa Eyodwa/Private Bag X 504, MOUNT AYLIFF 4735 
____________________________________________________________________________ 
PHARMACY DEPARTMENT 
 
Informed consent form for a study on the Quantitative assessment of the prevalence of 
mitochondrial toxicity in HIV/AIDS patients initiated on a Stavudine containing regimen in 
Mount Ayliff Hospital ARV clinic 
 
INFORMATION SHEET:   
 
INTRODUCTION:  The South African ART guideline employs d4T as the first line treatment 
in the management of HIV/AIDS. The prevalence of the toxicities on this patient population 
impact on the success of the ART programme, and affect the quality of life of the patients. The 
study aims to establish a quantitative assessment for the prevalence of mitochondrial toxicity as 
a result of d4T use in ARV regimes. 
 
PURPOSE: The study hopes to create an awareness of the early detection of symptoms 
associated with mitochondrial toxicity, thus enable optimization of clinical outcomes, whilst 
maintaining adherence and compliance to therapy. Furthermore, in-service training of clinicians 
for Pharmacovigilance protocols can be improved. Finally, this research may be used in 
assessing the risk profile before initiating patients on a d4T-containing regimen. 
 
PARTICIPANT SELECTION: Participants on d4T-containng regimens have been identified 
for selection at the Mount Ayliff Hospital ARV clinic.  
 
VOLUNTARY PARTICIPATION: Participation is voluntary and it is the participant’s choice 
to be involved in the study. Standard treatment will continue, regardless of participation. 
 
PROCEDURES AND PROTOCOLS: A descriptive study will be conducted using data 
collected from all participants experiencing peripheral neuropathy, lipoatrophy and lactic 
acidosis in Mount Ayliff Hospital ARV clinic. The data will be obtained from participant 
patient files, based on subjective assessment of participants by the supervising health care 
professional. 
 
CONFIDENTIALITY: Confidentiality is ensured for all data employed. Information regarding 
the participants’ status, ARV therapy, etc will be employed for statistical purposes only. 
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RIGHT TO REFUSE OR WITHDRAW: Participation is entirely voluntary and participants 
have the right to withdraw or refuse involvement in the study at any time. 
This proposal has been reviewed and approved by management and quality assurance 
committee of the hospital through the medical manager after approval by the Departmental 
Research Committee and the University Ethics Committee.  
 
1. I agree to take part in the above research.  I have read the Participant Information Sheet 
which is attached to this form.  I understand what my role will be in this research, and 
all my questions have been answered to my satisfaction. 
 
2. I understand that I am free to withdraw from the research at any time, for any reason and 
without prejudice. 
 
3. I have been informed that the confidentiality of the information I provide will be 
safeguarded. 
 
4. I am free to ask any questions at any time before and during the study. 
 
5. I have been provided with a copy of this form and the Participant Information Sheet. 
 
Name of participant (print)………………………….Signed………………..….Date……………… 
 
Name of witness (print)……………………………..Signed………………..….Date……………… 
 
YOU WILL BE GIVEN A COPY OF THIS FORM TO KEEP 
I have read the foregoing information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntarily to participate as a participant in this research and 
understand that I have the right to withdraw from the research at any time without in any way 
affecting my medical care.  
 
If illiterate  
A literate witness must sign (if possible, this person should be selected by the participant and should have no connection to the research team).  
 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
Print name of witness_____________________ AND Thumb print of participant 
Signature of witness ______________________  
Date ________________________  
 
 
I have accurately read or witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.  
 
 
Print Name of Researcher________________________  
Signature of Researcher _________________________  
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Date ___________________________  
A copy of this Informed Consent Form has been provided to participant _____ (initialled by the 
researcher/assistant). 
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Appendix E.  Consent for the Use of Pharmacy Folders for Perusal 
 
MOUNT AYLIFF HOSPITAL 
Batho Pele /Abantu Kuqala/People First 
ISEBE LEZEMPILO DEPARTMENT OF HEALTH 
Ingxowa Eyodwa/Private Bag X 504, MOUNT AYLIFF 4735 
____________________________________________________________________________ 
PHARMACY DEPARTMENT 
 
Consent for the use of pharmacy folders for perusal 
Research topic: 
1. I agree to assist in the above research by providing appropriate and relevant patient 
information.    I understand my role as a pharmacist in this research. 
 
2. I understand that I am free to withdraw a patient folder and information, for any reason 
and without prejudice. 
 
3. I am bound by the pharmaceutical legislation of my profession to maintain patient 
confidentiality and dignity at all times. 
 
4. I have been provided with a copy of this form and the Participant Information Sheet. 
 
Print Name of Pharmacist________________________  
Signature of Pharmacist _________________________  
Date ___________________________  
A signed copy of this Informed Consent Form will be added to the patient folder for future 
reference. 
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F.   Ethical Clearance form 
 
